Biocon Limited has informed the Exchange regarding allotment of 17,12,79,553 equity shares pursuant to Preferential Issue at its meeting held on January 05, 2026
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.1 pts less than Nifty Midcap 150 and 1.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Biocon has completed the acquisition of 26,19,17,480 equity shares (about 49% stake) of its unlisted subsidiary Biocon Biologics Limited (BBL) from four sellers: Mylan Inc., Serum Institute Life Sciences, Tata Capital Growth Fund II, and Activ Pine LLP. As consideration (share swap), Biocon issued 17,12,79,553 fresh equity shares at Rs. 405.78 per share, raising its paid-up capital from Rs. 668.48 crore to Rs. 754.12 crore (shares rose from 133.7 crore to 150.8 crore). Mylan now holds 6.10%, Serum Institute 3.68%, Tata Capital Growth Fund II 0.41%, and Activ Pine LLP 1.17% in Biocon, taking combined non-promoter shareholding to 11.36%. Additionally, Biocon paid USD 200 million in cash to Mylan for another 7.18 crore BBL shares, taking its total BBL holding to ~94% on a fully diluted basis (out of a previously approved USD 400 million cash deal).
This is a non-cash, share-swap-based consolidation that modestly dilutes existing shareholders (~12.8% dilution from new shares) but increases Biocon's effective economic interest in its high-value biologics subsidiary from roughly 70% to ~94%, which should be value-accretive over time. The stock may see some short-term supply pressure from the new allottees but benefits from simpler group structure and fuller ownership of BBL's future upside.